APO Research
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Stimulant Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Central Nervous System (CNS) Stimulant Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025199 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Stimulant Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Stimulant Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Stimulant Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Stimulant Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Stimulant Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Central Nervous System (CNS) Stimulant Drugs include Takeda Pharmaceuticals, Sanofi, Thermo Fisher Scientific, Johnson and Johnson, Novartis, Merck, Roche, Eli Lilly and Company and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Central Nervous System (CNS) Stimulant Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Central Nervous System (CNS) Stimulant Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Central Nervous System (CNS) Stimulant Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Central Nervous System (CNS) Stimulant Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Central Nervous System (CNS) Stimulant Drugs Segment by Company

Takeda Pharmaceuticals

Sanofi

Thermo Fisher Scientific

Johnson and Johnson

Novartis

Merck

Roche

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Biogen

Shire

Perdue Pharma

Celltech

Astellas Pharma

Central Nervous System (CNS) Stimulant Drugs Segment by Type

Cocaine

Caffeine

Amphetamine

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Application

Attention Deficit Hyperactivity Disorder (ADHD)

Narcolepsy

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Stimulant Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Stimulant Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Stimulant Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Central Nervous System (CNS) Stimulant Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Central Nervous System (CNS) Stimulant Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Central Nervous System (CNS) Stimulant Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Central Nervous System (CNS) Stimulant Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Central Nervous System (CNS) Stimulant Drugs Industry Trends Table 2. Central Nervous System (CNS) Stimulant Drugs Industry Drivers Table 3. Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges Table 4. Central Nervous System (CNS) Stimulant Drugs Industry Restraints Table 5. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers (tons) & (2021-2026) Table 8. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Manufacturers Table 9. Global Central Nervous System (CNS) Stimulant Drugs Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Central Nervous System (CNS) Stimulant Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Central Nervous System (CNS) Stimulant Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Central Nervous System (CNS) Stimulant Drugs Manufacturers, Product Type & Application Table 13. Global Central Nervous System (CNS) Stimulant Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Central Nervous System (CNS) Stimulant Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cocaine Table 17. Major Manufacturers of Caffeine Table 18. Major Manufacturers of Amphetamine Table 19. Major Manufacturers of Others Table 20. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type 2021 VS 2025 VS 2032 (tons) Table 21. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 22. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 23. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2021-2026) Table 24. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2027-2032) Table 25. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type 2021 VS 2025 VS 2032 (tons) Table 26. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2026) & (tons) Table 27. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2027-2032) & (tons) Table 28. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Attention Deficit Hyperactivity Disorder (ADHD) Table 31. Major Manufacturers of Narcolepsy Table 32. Major Manufacturers of Others Table 33. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application 2021 VS 2025 VS 2032 (tons) Table 34. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 35. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 36. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2021-2026) Table 37. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2027-2032) Table 38. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application 2021 VS 2025 VS 2032 (tons) Table 39. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2026) & (tons) Table 40. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2027-2032) & (tons) Table 41. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 44. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2026) & (tons) Table 45. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2021-2026) Table 46. Global Central Nervous System (CNS) Stimulant Drugs Sales Forecasted by Region (2027-2032) & (tons) Table 47. Global Central Nervous System (CNS) Stimulant Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 49. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 50. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 51. Europe Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 52. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 53. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 54. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 55. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 56. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 57. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 58. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 59. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 60. Global Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2027-2032) Table 65. Takeda Pharmaceuticals Company Information Table 66. Takeda Pharmaceuticals Business Overview Table 67. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 69. Takeda Pharmaceuticals Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 74. Sanofi Recent Development Table 75. Thermo Fisher Scientific Company Information Table 76. Thermo Fisher Scientific Business Overview Table 77. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 79. Thermo Fisher Scientific Recent Development Table 80. Johnson and Johnson Company Information Table 81. Johnson and Johnson Business Overview Table 82. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 84. Johnson and Johnson Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 89. Novartis Recent Development Table 90. Merck Company Information Table 91. Merck Business Overview Table 92. Merck Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 94. Merck Recent Development Table 95. Roche Company Information Table 96. Roche Business Overview Table 97. Roche Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 99. Roche Recent Development Table 100. Eli Lilly and Company Company Information Table 101. Eli Lilly and Company Business Overview Table 102. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 104. Eli Lilly and Company Recent Development Table 105. Pfizer Company Information Table 106. Pfizer Business Overview Table 107. Pfizer Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 109. Pfizer Recent Development Table 110. GlaxoSmithKline Company Information Table 111. GlaxoSmithKline Business Overview Table 112. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 114. GlaxoSmithKline Recent Development Table 115. Biogen Company Information Table 116. Biogen Business Overview Table 117. Biogen Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 119. Biogen Recent Development Table 120. Shire Company Information Table 121. Shire Business Overview Table 122. Shire Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 124. Shire Recent Development Table 125. Perdue Pharma Company Information Table 126. Perdue Pharma Business Overview Table 127. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 129. Perdue Pharma Recent Development Table 130. Celltech Company Information Table 131. Celltech Business Overview Table 132. Celltech Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 134. Celltech Recent Development Table 135. Astellas Pharma Company Information Table 136. Astellas Pharma Business Overview Table 137. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 139. Astellas Pharma Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Central Nervous System (CNS) Stimulant Drugs Distributors List Table 143. Central Nervous System (CNS) Stimulant Drugs Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Stimulant Drugs Product Image Figure 2. Global Central Nervous System (CNS) Stimulant Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Stimulant Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Central Nervous System (CNS) Stimulant Drugs Sales (2021-2032) & (tons) Figure 5. Global Central Nervous System (CNS) Stimulant Drugs Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Central Nervous System (CNS) Stimulant Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cocaine Image Figure 9. Caffeine Image Figure 10. Amphetamine Image Figure 11. Others Image Figure 12. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 13. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021 VS 2025 VS 2032) & (tons) Figure 16. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2021-2032) Figure 18. Attention Deficit Hyperactivity Disorder (ADHD) Image Figure 19. Narcolepsy Image Figure 20. Others Image Figure 21. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 22. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021 VS 2025 VS 2032) & (tons) Figure 25. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 28. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 30. Canada Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 31. Mexico Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 32. Europe Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 33. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 35. France Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 36. U.K. Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 37. Italy Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 38. Netherlands Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 39. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 40. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2032) Figure 41. China Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 42. Japan Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 43. South Korea Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 44. Southeast Asia Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 45. India Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 46. Australia Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 47. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 48. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 50. South Africa Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 51. Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 52. Turkey Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 53. Argentina Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 54. UAE Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 55. Egypt Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 56. Chile Central Nervous System (CNS) Stimulant Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 57. Global Central Nervous System (CNS) Stimulant Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Central Nervous System (CNS) Stimulant Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Central Nervous System (CNS) Stimulant Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Cocaine
  • Caffeine
  • Amphetamine
  • Others
Applications
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Narcolepsy
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Sanofi
  • Thermo Fisher Scientific
  • Johnson and Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Shire
  • Perdue Pharma
  • Celltech
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Central Nervous System (CNS) Stimulant Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Central Nervous System (CNS) Stimulant Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Central Nervous System (CNS) Stimulant Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Central Nervous System (CNS) Stimulant Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Central Nervous System (CNS) Stimulant Drugs Market Dynamics
  1. 2.1 Central Nervous System (CNS) Stimulant Drugs Industry Trends
  2. 2.2 Central Nervous System (CNS) Stimulant Drugs Industry Drivers
  3. 2.3 Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Stimulant Drugs Industry Restraints
3 Central Nervous System (CNS) Stimulant Drugs Market by Manufacturers
  1. 3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Central Nervous System (CNS) Stimulant Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Central Nervous System (CNS) Stimulant Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Central Nervous System (CNS) Stimulant Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Central Nervous System (CNS) Stimulant Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Central Nervous System (CNS) Stimulant Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Central Nervous System (CNS) Stimulant Drugs Tier 1, Tier 2, and Tier 3
4 Central Nervous System (CNS) Stimulant Drugs Market by Type
  1. 4.1 Central Nervous System (CNS) Stimulant Drugs Type Introduction
  2. 4.1.1 Cocaine
  3. 4.1.2 Caffeine
  4. 4.1.3 Amphetamine
  5. 4.1.4 Others
  6. 4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type
  7. 4.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type
  11. 4.3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2021-2032)
5 Central Nervous System (CNS) Stimulant Drugs Market by Application
  1. 5.1 Central Nervous System (CNS) Stimulant Drugs Application Introduction
  2. 5.1.1 Attention Deficit Hyperactivity Disorder (ADHD)
  3. 5.1.2 Narcolepsy
  4. 5.1.3 Others
  5. 5.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application
  6. 5.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application
  10. 5.3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2021-2032)
6 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region
  1. 6.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region
  1. 7.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region
  2. 7.1.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032)
  8. 7.2.2 North America Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Thermo Fisher Scientific
  14. 8.3.1 Thermo Fisher Scientific Company Information
  15. 8.3.2 Thermo Fisher Scientific Business Overview
  16. 8.3.3 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  18. 8.3.5 Thermo Fisher Scientific Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly and Company
  44. 8.8.1 Eli Lilly and Company Company Information
  45. 8.8.2 Eli Lilly and Company Business Overview
  46. 8.8.3 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  48. 8.8.5 Eli Lilly and Company Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Biogen
  62. 8.11.1 Biogen Company Information
  63. 8.11.2 Biogen Business Overview
  64. 8.11.3 Biogen Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  66. 8.11.5 Biogen Recent Developments
  67. 8.12 Shire
  68. 8.12.1 Shire Company Information
  69. 8.12.2 Shire Business Overview
  70. 8.12.3 Shire Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  72. 8.12.5 Shire Recent Developments
  73. 8.13 Perdue Pharma
  74. 8.13.1 Perdue Pharma Company Information
  75. 8.13.2 Perdue Pharma Business Overview
  76. 8.13.3 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  78. 8.13.5 Perdue Pharma Recent Developments
  79. 8.14 Celltech
  80. 8.14.1 Celltech Company Information
  81. 8.14.2 Celltech Business Overview
  82. 8.14.3 Celltech Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  84. 8.14.5 Celltech Recent Developments
  85. 8.15 Astellas Pharma
  86. 8.15.1 Astellas Pharma Company Information
  87. 8.15.2 Astellas Pharma Business Overview
  88. 8.15.3 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  90. 8.15.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Central Nervous System (CNS) Stimulant Drugs Value Chain Analysis
  2. 9.1.1 Central Nervous System (CNS) Stimulant Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Central Nervous System (CNS) Stimulant Drugs Production Mode & Process
  6. 9.2 Central Nervous System (CNS) Stimulant Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Central Nervous System (CNS) Stimulant Drugs Distributors
  9. 9.2.3 Central Nervous System (CNS) Stimulant Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst